Clinical Roundup Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials May 24, 2024Vol.50 No.21
Clinical Roundup Vepdegestrant + Ibrance continue to show clinical benefit for ER+/HER2- breast cancer in phase Ib trial May 24, 2024Vol.50 No.21
Clinical Roundup NCCN publishes patient resource for small bowel adenocarcinoma May 24, 2024Vol.50 No.21
Clinical Roundup NCCN and Polish oncology groups to adapt NCCN Guidelines for Poland May 24, 2024Vol.50 No.21
Drugs & Targets FDA advisory committee recommends approval of Shield blood test for colorectal cancer screening May 24, 2024Vol.50 No.21
Drugs & Targets FDA withdraws accelerated approval of infigratinib for metastatic cholangiocarcinoma with FGFR2 May 24, 2024Vol.50 No.21
Drugs & Targets FDA forms OCE Equity Program to improve clinical trial access May 24, 2024Vol.50 No.21
HRD results can vary widely, depending on what assay you choose—even as they guide treatment choices May 17, 2024Vol.50 No.20By Jacquelyn Cobb
